ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

New insights into the burden and costs of multiple sclerosis in Europe

(2017) Gisela Kobelt et al.   Multiple Sclerosis Journal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

New insights into the burden and costs of multiple sclerosis in Europe

(2017) Gisela Kobelt et al.   Multiple Sclerosis Journal

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

(2016) Vilija G. Jokubaitis et al.   ANNALS OF NEUROLOGY

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Adapting the nominal group technique for priority setting of evidence-practice gaps in implementation science

(2016) Nicole M. Rankin et al.   BMC Medical Research Methodology

Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study

(2016) Susan Friend et al.   BMC Neurology

Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod

(2016) M. E. Evangelopoulos et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation

(2016) Bianca Weinstock-Guttman et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

(2016) Ilya Kister et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis

(2016) Jordi Río et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Glatiramer acetate during early pregnancy: A prospective cohort study

(2016) Sandra Herbstritt et al.   Multiple Sclerosis Journal

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

(2016) Ralf Gold et al.   Multiple Sclerosis Journal

Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry

(2016) Sandra Thiel et al.   Multiple Sclerosis Journal

Disease-modifying therapies and infectious risks in multiple sclerosis

(2016) Alexander Winkelmann et al.   Nature Reviews Neurology

Assessing response to interferon-β in a multicenter dataset of patients with MS

(2016) Maria Pia Sormani et al.   NEUROLOGY

International Pediatric MS Study Group Global Members Symposium report: Table

(2016) Evangeline Wassmer et al.   NEUROLOGY

Consensus definitions for pediatric MS and other demyelinating disorders in childhood: Table

(2016) Marc Tardieu et al.   NEUROLOGY

Long-term safety and efficacy of teriflunomide

(2016) Paul O'Connor et al.   NEUROLOGY

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial

(2016) Ludwig Kappos et al.   NEUROLOGY

Pregnancy outcomes in Lebanese women with multiple sclerosis (the LeMS study): a prospective multicentre study

(2016) Jawad Fares et al.   BMJ Open

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment

(2016) Stacy Ellen Hatcher et al.   JAMA Neurology

Glatiramer acetate during early pregnancy: A prospective cohort study

(2016) Sandra Herbstritt et al.   Multiple Sclerosis Journal

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

(2016) Ralf Gold et al.   Multiple Sclerosis Journal

Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry

(2016) Sandra Thiel et al.   Multiple Sclerosis Journal

Defining high, medium and low impact prognostic factors for developing multiple sclerosis

(2015) Mar Tintore et al.   BRAIN

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

(2015) Pietro Iaffaldano et al.   BRAIN

Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis

(2015) Adnan M. Subei et al.   CNS DRUGS

Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS)

(2015) B. Yamout et al.   CURRENT MEDICAL RESEARCH AND OPINION

Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients

(2015) M. Romeo et al.   EUROPEAN JOURNAL OF NEUROLOGY

Practical recommendations for the process of proposing, planning and writing a neurological management guideline by EAN task forces

(2015) M. A. Leone et al.   EUROPEAN JOURNAL OF NEUROLOGY

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

(2015) Stefan Braune et al.   JOURNAL OF NEUROLOGY

High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991–2010)

(2015) Elaine Kingwell et al.   JOURNAL OF NEUROLOGY

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

(2015) Jeffrey A Cohen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

(2015) J Kuhle et al.   Multiple Sclerosis Journal

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

(2015)   Nature Reviews Neurology

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial

(2015) L. Kappos et al.   NEUROLOGY

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2015) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Utility of the Rio Score and Modified Rio Score in Korean Patients with Multiple Sclerosis

(2015) Jae-Won Hyun et al.   PLoS One

The indirect costs of multiple sclerosis: systematic review and meta-analysis

(2015) Ewa Stawowczyk et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

(2015) Anna He et al.   JAMA Neurology

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

(2015) J Kuhle et al.   Multiple Sclerosis Journal

What to expect after natalizumab cessation in a real-life setting

(2014) S. Salhofer-Polanyi et al.   ACTA NEUROLOGICA SCANDINAVICA

Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids

(2014) Silvia Rossi et al.   CNS Neuroscience & Therapeutics

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy

(2014) Simon A. Broadley et al.   JOURNAL OF CLINICAL NEUROSCIENCE

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

(2014) T. L. Vollmer et al.   JOURNAL OF NEUROLOGY

Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis

(2014) A. Gueguen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Pregnancy outcomes in patients exposed to interferon beta-1b: Table 1

(2014) Rebecca S Romero et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Management of relapsing–remitting multiple sclerosis in Latin America: Practical recommendations for treatment optimization

(2014) Jorge Correale et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

(2014) Gavin Giovannoni et al.   LANCET NEUROLOGY

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Aaron E Miller et al.   LANCET NEUROLOGY

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Christian Confavreux et al.   LANCET NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Significant clinical worsening after natalizumab withdrawal: Predictive factors

(2014) A Vidal-Jordana et al.   Multiple Sclerosis Journal

Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study

(2014) Neda Ebrahimi et al.   Multiple Sclerosis Journal

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

(2014) Bernd C Kieseier et al.   Multiple Sclerosis Journal

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

(2014) R. J. Fox et al.   NEUROLOGY

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

(2014) G. Karlsson et al.   NEUROLOGY

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

(2014) P. Browne et al.   NEUROLOGY

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study

(2014) Niklas Bergvall et al.   PLoS One

Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events

(2014) P K Coyle et al.   BMJ Open

Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab

(2014) Marinella Clerico et al.   JAMA Neurology

Switching From Natalizumab to Fingolimod in Multiple Sclerosis

(2014) Mikael Cohen et al.   JAMA Neurology

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

(2014) Edward Fox et al.   Multiple Sclerosis and Related Disorders

Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients

(2014) Francesca Sangalli et al.   Multiple Sclerosis and Related Disorders

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

(2013) Omar Khan et al.   ANNALS OF NEUROLOGY

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS

(2013) Jeffrey A. Cohen et al.   JOURNAL OF NEUROLOGY

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT

(2013) G. Edan et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions

(2013) Lauren B Krupp et al.   Multiple Sclerosis Journal

Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis

(2013) Luca Prosperini et al.   Multiple Sclerosis Journal

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

(2013) Patrick Vermersch et al.   Multiple Sclerosis Journal

Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up

(2013) Marta Melis et al.   NEUROLOGICAL SCIENCES

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study

(2012) Marta Giannini et al.   BMC Neurology

The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis

(2012) Yara Dadalti Fragoso et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

(2012) J. Río et al.   EUROPEAN JOURNAL OF NEUROLOGY

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

(2012) Joachim Havla et al.   JOURNAL OF NEUROLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings

(2012) F Rinaldi et al.   Multiple Sclerosis Journal

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

(2012) Giancarlo Comi et al.   Multiple Sclerosis Journal

Scoring treatment response in patients with relapsing multiple sclerosis

(2012) MP Sormani et al.   Multiple Sclerosis Journal

Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review

(2012) E. Lu et al.   NEUROLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple sclerosis and pregnancy: experience from a nationwide database in Germany

(2012) Kerstin Hellwig et al.   Therapeutic Advances in Neurological Disorders

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis

(2011) Carmen Tur   ARCHIVES OF NEUROLOGY

Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study

(2011) G. Borriello et al.   EUROPEAN JOURNAL OF NEUROLOGY

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

(2011) Gordon Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study

(2011) María José Magraner et al.   JOURNAL OF NEUROLOGY

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

(2011) Bhupendra Khatri et al.   LANCET NEUROLOGY

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

(2011) Giancarlo Comi et al.   LANCET NEUROLOGY

Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs

(2011) E Lu et al.   Multiple Sclerosis Journal

Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis

(2011) M Calabrese et al.   Multiple Sclerosis Journal

Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment

(2011) Kerstin Hellwig et al.   Multiple Sclerosis Journal

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis

(2011) Luca Prosperini et al.   Multiple Sclerosis Journal

Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis

(2011) T Chitnis et al.   Multiple Sclerosis Journal

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natalizumab dosage suspension: Are we helping or hurting?

(2010) Timothy W. West et al.   ANNALS OF NEUROLOGY

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy

(2010) Augusto Miravalle et al.   ARCHIVES OF NEUROLOGY

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

(2010) G. C. Ebers et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Observations during an elective interruption of natalizumab treatment: a post-marketing study

(2010) Giovanna Borriello et al.   Multiple Sclerosis Journal

Pregnancy and fetal outcomes after interferon-  exposure in multiple sclerosis

(2010) M. P. Amato et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

(2009) L. Prosperini et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

(2009) Ludwig Kappos et al.   LANCET NEUROLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study)

(2009) N Fernández Liguori et al.   Multiple Sclerosis Journal

Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study

(2009) C Weber-Schoendorfer et al.   Multiple Sclerosis Journal

Clinical prognostic factors in multiple sclerosis: a natural history review

(2009) Alexandra Degenhardt et al.   Nature Reviews Neurology

Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

(2009) D. Cadavid et al.   NEUROLOGY

Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?

(2008) F. Patti et al.   JOURNAL OF NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal